Review Question - QID 109981

A pharmaceutical company is studying a new drug that inhibits the glucose transporter used by intestinal enterocytes to absorb glucose into the body. The drug was designed such that it would act upon the glucose transporter similarly to how cyanide acts upon cytochrome proteins. During pre-clinical studies, the behavior of this drug on the activity of the glucose transporter is examined. Specifically, enterocyte cells are treated with the drug and then glucose is added to the solution at a concentration that saturates the activity of the transporter. The transport velocity and affinity of the transporters under these conditions are then measured. Compared to the untreated state, which of the following changes would most likely be seen in these transporters after treatment?